MedTrace Logo

A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

NCT02428036 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-07-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether TBI-1401(HF10), a spontaneously attenuated mutant of Herpes Simplex Virus Type 1 (HSV-1), is safe and tolerable in the treatment of solid tumors with superficial lesions.

Conditions

Interventions

BIOLOGICAL

TBI-1401(HF10)

Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^6 TCID50/mL.

BIOLOGICAL

TBI-1401(HF10)

Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10\^7 TCID50/mL.

Sponsors & Collaborators

  • Takara Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Naoya Yamazaki · National Cancer Center Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-10-31
Completion
2017-06-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428036 on ClinicalTrials.gov